Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
library@mnums.edu.mn
/

Gunchin, Batbaatar

Loading...
Thumbnail Image
Товч нэр
Gunchin, Batbaatar
Бүтэн нэр
Gunchin Batbaatar
Латин нэр
Gunchin Batbaatar
Албан тушаал
Судлаач
Харьяалал
ORCID
Scopus Author ID

Settings

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Treatment of Chronic HCV Infection with Direct Acting Antivirals
    (Mongolian National University of Medical Sciences, 2021-09-21)
    Bekhbold Dashtseren
    ;
    Zulkhuu Genden
    ;
    Odgerel Oidovsambuu
    ;
    Anir Enkhbat
    ;
    Ganbolor Jargalsaikhan
    Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs). Methods: Based on the Liver Center database, we studied the treatment effect of Sofosbuvir 400 mg/Ledipasvir 90 mg in 1109 patients with chronic hepatitis C virus infection during the time period from December 2015 to December, 2018. Results: In patients treated with Sofosbuvir/Ledipasvir, the sustained viral load (SVR12) was 97.9% (1086/1109) 12 weeks after the treatment. The SVR12 was 99.2% (845/851) in HCV-infected non-cirrhotic patients, 93.4% (241/258) in patients with cirrhosis, and 80% (8/10) among patients treated for liver cancer. The SVR12 (19/25) was lowered to 76% at 12 weeks of treatment with Sofosbuvir 400 mg/ Daclatasvir 60 mg in DAA-failure patients 23/1109 (2.07%). Conclusions: SVR12 rates in non-cirrhotic and cirrhotic patients were 99.2% and 93.4%, respectively, while it was 80% in liver cancer patients after DAA treatment. As for patients with viral relapse, 76% of them were successfully retreated with second-line DAA treatment. During the DAA treatment, only 17.6% of all patients had some adverse effects related to DAA treatment, thus, DAA treatment is suitable for Mongolian patients and has less adverse effects.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Elevated Ammonia Level as a Diagnostic Marker of Hepatic Encephalopathy
    (Mongolian National University of Medical Sciences, 2016-06-25)
    Ochirkhuree, Bayarmaa
    ;
    Namdag, Bira
    ;
    Jambal, Sarangerel
    ;
    Gunchin, Batbaatar
    Objectives: Hepatic encephalopathy (HE) is a common and prognostic complication of cirrhosis. It may reflect either a reversible metabolic encephalopathy, brain atrophy, edema or any combination of these conditions. The mechanisms causing brain dysfunction in liver failure are still unknown. Ammonia is the best-characterized neurotoxin that precipitates HE. The purpose of this study was to ascertain the role of ammonia in HE. Methods: A hospital-based prospective study on HE was carried out at the First Central Hospital of Mongolia and the Chingeltei-Uul District Hospital in 2011-2013. Patients with hepatic failure were subdivided into the three following groups: (1) patients without HE, (2) patients with grade l-ll HE, (3) patients with grade lll-IV HE. We took liver function tests, Model for End-Stage Liver Disease (MELD) score and blood ammonia and correlated them with the severity of encephalopathy. The mean variables ±SD, p-values, and Pearson coefficients were calculated by SPSS 17.0. Results: The total sample size was 120 and the mean age was 36.8 ±15.4 years. Elevated ammonia level was observed in every stage of HE and increased by stage (p< 0.0001) MELD score and elevated ammonia level had a strong positive correlation (r = 0.54, p = 0.0001). In patients with any infection, the ammonia level was higher (p< 0.0001) than other groups. Conclusion: Ammonia is one of the diagnostic biomarkers of HE.